Cancer Experts Detail How 'Big Data' Plays a Critical Role in Improving Clinical Decision-Making in Oncology Treatments at 3rd ESTRO Forum
Varian Medical Systems CEO Dow Wilson Pushes for Healthcare Infrastructure Investment in Africa
Foxconn expanding into health-care market
Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.
Varian Medical Systems' VAR third-quarter results were in line with our expectations, and we are leaving our fair value estimate unchanged. Overall, revenue increased 7%, and net orders rose 13%, bringing the company's backlog at quarter-end to $1.6 billion. Revenue for the oncology system segment ...
While the sector looks slightly overvalued overall, we still see several stocks that offer attractive valuations across the different industries.
Varian Medical's VAR third-quarter fiscal 2006 results fall right in line with the seasonal patterns we expected from our current near-term modeling assumptions. The oncology group notched 14% growth, and customer demand continues to reflect a shift toward Varian's next-generation IGRT technology, ...
The combination makes plenty of sense and should better position the firm for the future.